0001127602-17-026940.txt : 20170905 0001127602-17-026940.hdr.sgml : 20170904 20170905154027 ACCESSION NUMBER: 0001127602-17-026940 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170831 FILED AS OF DATE: 20170905 DATE AS OF CHANGE: 20170905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sheridan William P CENTRAL INDEX KEY: 0001439174 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 171068631 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-08-31 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001439174 Sheridan William P 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior VP - CMO Emp. Stock Option (Right to Buy) 11.13 2017-08-31 4 A 0 33900 0 A 2017-08-31 2024-12-22 Common Stock 33900 33900 D On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. /s/ Alane P. Barnes, by power of attorney 2017-09-05